Exposure–safety–efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study

Overview of attention for article published in Investigational New Drugs, April 2016

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (55th percentile)
Above-average Attention Score compared to outputs of the same age and source (61st percentile)

Mentioned by

wikipedia: 4 Wikipedia pages

Citations

dimensions_citation: 19 Dimensions

Readers on

mendeley: 35 Mendeley

Summary Wikipedia Dimensions citations

So far, Altmetric has seen 4 citations on 4 Wikipedia pages.

Ixazomib

Cited by user Ptthnhan on 17 Aug 2019

ایکسازومیب

Cited by user Tisfoon on 05 Apr 2018

Ixazomib

Cited by user Caperucitagris on 19 Oct 2017

Ixazomib

Cited by user Anypodetos on 04 Jan 2017

Ixazomib (trade name Ninlaro) is a drug for the treatment of multiple myeloma, developed by Takeda.

This page shows the most recent Wikipedia articles that mention this research output.

Click here to find out how to access more activity.